Nasdaq-listed Repligen to create 130 new jobs in Waterford

Repligen is set to significantly expand its manufacturing operations in Waterford in a move that will lead to the creation of 130 new jobs over the next two and a half years.

The Nasdaq-listed company, which acquired Waterford-headquartered Artseyn Biosolutions in a $200 million (€170 million) deal late last year, plans to fit out a 33,000 square foot building to serve as a centre of excellence for single-use consumable products used in bioprocessing applications.

The new facility will complement the 975.4 sq m (10,500 sq ft) site that Repligen acquired as part of the deal for Artseyn. That site employs 74 people currently.

Headquartered in Massachusetts, Repligen is a life sciences company that was founded in 1981. It recorded revenues of $366 million last year. Known for its single-use bioprocessing technologies that increase efficiencies in the process of manufacturing biological drugs, the company plans to invest in building out the new Waterford plant as an innovation, assembly and production centre for a diverse portfolio of “plug-and-play” consumables, for use with state-of-the-art filtration and chromatography systems.

Bausch & Lomb to invest €90m and create 130 jobs at Waterford plant

---

Drug distributors to pay up to $1.1bn in New York opioid case settlement

---

Like Caesar’s wife, FDA must be above suspicion

---

Johnson & Johnson pencils in €2.1bn in Covid-19 vaccine sales

---

The expansion plan is supported by the Government through IDA Ireland.

"This buildout is an important step in expanding our capacity and establishing dual manufacturing sites for key single-use consumable products used in manufacture of biological drugs," said James Bylund, senior vice-president, global operations and information technology at Repligen.